Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Clinigen Group PLC    CLIN   GB00B89J2419

CLINIGEN GROUP PLC (CLIN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Clinigen : boost unlicensed drugs business with Quantum takeover

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/13/2017 | 09:57am CEST

LONDON (Reuters) - Britain's Clinigen Group on Wednesday agreed to buy Quantum Pharma for 150.3 million pounds, bringing together two companies that specialise in the supply of unlicensed medicines to doctors and hospitals.

Clinigen said the deal would accelerate its global ambitions in the ethical supply of unlicensed medicines - drugs that are either in clinical trials or are licensed in other markets - to doctors who want to use them for their patients.

Chief Executive Shaun Chilton said it would also increase its ability to convert unlicensed drugs into licensed products.

"(Quantum) introduces an unlicensed medicine in the initial stages to cope with an unmet need and it converts it into a licensed medicine," he said in an interview.

"That unlicensed-to-licensed piece acts as a bridge between two of our business operations: our unlicensed medicines division and our commercial medicines division."

Quantum shareholders will receive 37 pence in cash and 0.0405 new Clinigen shares for each share, valuing each Quantum share at 82 pence, Clinigen said.

Quantum, which installed a new management team in October 2016 after a period of underperformance, reported revenue from continuing operations of 36.2 million pounds for the six months to end-July and adjusted core earnings of 5.7 million pounds.

Shares in Quantum rose 17.5 percent to 78 pence in early deals. Clinigen was trading down 1.4 percent.

(Reporting by Paul Sandle; editing by Jason Neely)

Stocks treated in this article : Clinigen Group PLC, Quantum Pharma PLC
Stocks mentioned in the article
ChangeLast1st jan.
QUANTUM PHARMA PLC 0.00%-End-of-day quote.0.00%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CLINIGEN GROUP PLC
06/18CLINIGEN : Signs exclusive supply and distribution agreement with lukare for ell..
AQ
06/14CLINIGEN : signs exclusive supply & distribution agreement with Lukare for Ellio..
PU
06/04CLINIGEN : And bristol-myers squibb sign extended partnership agreement in south..
AQ
06/04CLINIGEN : Future Oncology publishes dexrazoxane article supporting EC removal o..
PU
05/31CLINIGEN : Extended partnership agreement signed with BMS
PU
05/31CLINIGEN : and Bristol-Myers Squibb sign extended partnership agreement in South..
PU
05/24Clinigen, Mitsubishi link for early access programme
AQ
05/24CLINIGEN : signs agreement with Nordic Pharma for aprotinin
BU
05/22CLINIGEN : and Mitsubishi Tanabe initiate European Managed Access Program for ed..
PU
04/17CLINIGEN : Receives pbs listing for trexject in australia for the treatment of r..
AQ
More news
News from SeekingAlpha
02/27Clinigen Group reports 1H results 
2017Clinigen Group reports FY results 
2017Clinigen Group reports Q4 results 
2016Clinigen Group reports FY16 results 
2016Clinigen acquires chemo reversing agent from Biocodex 
Financials ( GBP)
Sales 2018 359 M
EBIT 2018 65,6 M
Net income 2018 30,6 M
Debt 2018 126 M
Yield 2018 0,63%
P/E ratio 2018 31,85
P/E ratio 2019 20,82
EV / Sales 2018 3,27x
EV / Sales 2019 2,67x
Capitalization 1 048 M
Chart CLINIGEN GROUP PLC
Duration : Period :
Clinigen Group PLC Technical Analysis Chart | CLIN | GB00B89J2419 | 4-Traders
Technical analysis trends CLINIGEN GROUP PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 12,4  GBP
Spread / Average Target 46%
EPS Revisions
Managers
NameTitle
Shaun Edward Chilton Chief Executive Officer & Executive Director
Peter Vance Allen Non-Executive Chairman
Debra Ainge Chief Operating Officer
Martin Abell Chief Financial Officer & Executive Director
Ivo Timmermans Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
CLINIGEN GROUP PLC-16.80%1 380
GILEAD SCIENCES-1.97%89 796
VERTEX PHARMACEUTICALS3.44%38 655
REGENERON PHARMACEUTICALS-16.13%33 439
NEUROCRINE BIOSCIENCES, INC.31.87%9 196
GENMAB-6.69%9 076